+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Branch Retinal Vein Occlusion Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767283
  • Report
  • April 2019
  • Region: Global
  • 73 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Bayer AG
  • Clearside BioMedical Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Samsung Medical Center
  • MORE
The global clinical trial report- “2019 Branch Retinal Vein Occlusion Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Branch Retinal Vein Occlusion. It presents in-depth analysis of Branch Retinal Vein Occlusion clinical trials across markets and companies. The research work is for providing complete understanding into trends in Branch Retinal Vein Occlusion.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Branch Retinal Vein Occlusion clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Branch Retinal Vein Occlusion

The research work is prepared through extensive and continuous research on Branch Retinal Vein Occlusion trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Branch Retinal Vein Occlusion patients are identified
  • The report includes panorama of Branch Retinal Vein Occlusion clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Branch Retinal Vein Occlusion clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Bayer AG
  • Clearside BioMedical Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Samsung Medical Center
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Branch Retinal Vein Occlusion Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Branch Retinal Vein Occlusion Clinical Trials by Region
2.2.2 Average Enrollment of Branch Retinal Vein Occlusion Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Branch Retinal Vein Occlusion Treatment, 2019

3. Region wise Branch Retinal Vein Occlusion Clinical Trials
3.1 Asia Pacific Branch Retinal Vein Occlusion Clinical Trials by Country
3.2 Europe Branch Retinal Vein Occlusion Clinical Trials by Country
3.3 North America Branch Retinal Vein Occlusion Clinical Trials by Country
3.4 Middle East and Africa Branch Retinal Vein Occlusion Clinical Trials by Country
3.5 South and Central America Branch Retinal Vein Occlusion Clinical Trials by Country

4. Branch Retinal Vein Occlusion Clinical Trial Trends
4.1 Start Year wise Branch Retinal Vein Occlusion Clinical Trials
4.2 Phase wise Branch Retinal Vein Occlusion Clinical Trials
4.3 Trial Status wise Branch Retinal Vein Occlusion Clinical Trials
4.4 Trial Type wise Branch Retinal Vein Occlusion Clinical Trials

5. Branch Retinal Vein Occlusion Average Enrollment Trends
5.1 Average Enrollment in Branch Retinal Vein Occlusion Trials by Year
5.2 Average Enrollment in Branch Retinal Vein Occlusion Trials by Phase
5.3 Average Enrollment in Branch Retinal Vein Occlusion Trials by Status
5.4 Average Enrollment in Branch Retinal Vein Occlusion Trials by Type of Trial

6. Companies Participating in Branch Retinal Vein Occlusion Clinical Trials
6.1 Branch Retinal Vein Occlusion Trials by Sponsor Type
6.2 Branch Retinal Vein Occlusion Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Branch Retinal Vein Occlusion Trials- Phase 1
7.2 Branch Retinal Vein Occlusion Trials- Phase 2
7.3 Branch Retinal Vein Occlusion Trials- Phase 3
7.4 Branch Retinal Vein Occlusion Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Branch Retinal Vein Occlusion Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Figure 5: Europe - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Figure 7: North America - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Figure 9: Branch Retinal Vein Occlusion Clinical Trials by Phase
Figure 10: Branch Retinal Vein Occlusion Clinical Trials by Trial Status
Figure 11: Branch Retinal Vein Occlusion Clinical Trials by Type
Figure 12: Branch Retinal Vein Occlusion Clinical Trials by Sponsor Type
Figure 13: Branch Retinal Vein Occlusion Clinical Trials by Leading Sponsors
Figure 14: Branch Retinal Vein Occlusion Average Enrollment by Phase
Figure 15: Branch Retinal Vein Occlusion Average Enrollment by Trial Status
Figure 16: Branch Retinal Vein Occlusion Average Enrollment by Type
Figure 17: Branch Retinal Vein Occlusion- Average Enrolment by Type of Sponsors
Figure 18: Branch Retinal Vein Occlusion- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Branch Retinal Vein Occlusion Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Table 5: Europe - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Table 7: North America - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Branch Retinal Vein Occlusion Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Branch Retinal Vein Occlusion Average Enrollment by Phase
Table 15: Branch Retinal Vein Occlusion Average Enrollment by Trial Status
Table 16: Branch Retinal Vein Occlusion Average Enrollment by Type
Table 17: Branch Retinal Vein Occlusion- Average Enrolment by Type of Sponsors
Table 18: Branch Retinal Vein Occlusion- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan Plc
  • Bayer AG
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • China Resources Pharmaceutical Group Ltd
  • Clearside BioMedical Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Samsung Medical Center
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll